B-Cell Acute Lymphoblastic Leukemia (ALL), FISH, Bone Marrow
B-Cell Acute Lymphoblastic Leukemia (ALL) is a hematologic neoplasm that results from compromised differentiation, proliferation and accumulation of lymphoid progenitors in intramedullary (bone marrow) or extramedullary locations. Signs and symptoms reflect the degree of its spread, mostly fever, fatigue, bleeding, and bone or joint pain. Its incidence rate is 1.5 per 100,000 males and 1.2 for females annually. It is the most frequent leukemia in children, but most deaths occur in adults (80%).
The most common acquired genetic abnormality in children is hyperdiploidy (>50 chromosomes) with 23-29% frequency and a favorable outcome, and in adults it is BCR-ABL1 with 25-30% frequency and it is associated with poor outcome. Immunophenotyping classifies ALL into B-cell (80%) or T-cell (20%) subgroups.
Acquired genetic aberrations are a feature of ALL. These changes include ploidity (abnormal in the number of chromosomes) or alterations of chromosomal structure. The most frequent abnormality is translocations and others are inversions, deletions, point mutations, and amplifications.
Hyperdiploidy (>50 chromosomes) and t(12;21)(p13;q22)/ETV6-RUNX1(TEL-AML1) rearrangement comprise 23-29 % of the genetic aberrations in children, and 3-7% in adults with a favorable outcome. The most frequent aberration among adults with ALL is t(9;22)(q34;q11.2)/BCR-ABL1 translocation with 25-30% frequency. This rearrangement has a relatively lower frequency among children with 10% frequency and poor outcome. Another common translocation in two-thirds of infants with B-ALL is 11q23/MLL, with 1-2% and 4-9% incidence in older children and adults, respectively. t(1;19)(q23;p13.3)/TCF3(E2A)-PBX1 rearrangement has a frequency of 1-3% in adults, and 1-6% in children.
The most common recommended chromosomal abnormalities tested for a diagnosis of B-cell acute lymphoblastic leukemia by FISH are as follows: t(9;22), BCR/ABL1 11q23 rearrangement, MLL 9p-, CDKN2A/D9Z1 +4 / +10 / +17, D4Z1/D10Z1/D17Z1 t(12;21), ETV6/RUNX1 14q32 rearrangement, IGH t(1;19), PBX1/TCF3 17p-, TP53/D17Z1
The MLL aberration proceeds with identification of further translocations. These probes are t(11;19)(q23;p13.1) MLL/ELL, t(4;11)(q21;q23) AFF1/MLL, t(6;11)(q27;q23) MLLT4/MLL, t(10;11)(p12;q23) MLLT10/MLL, and t(11;19)(q23;p13.3) MLL/MLLT1, t(9;11)(p22;q23) MLLT3/MLL.
The probes to identify t(X;14)(p22.3;q32) or t(Y;14)(p11.32;q32) are used after the identification of IGH rearrangement.
Fluorescence in situ hybridization (FISH) is an additional molecular method for identification of chromosomal aberrations by usage of specific DNA probes against particular DNA sequences in the nucleus of interphase cells or metaphase chromosomes. It is a valuable molecular tool for assessment of prognosis with high sensitivity and specificity, rapid turnover with broad applications, and the capability to study non-dividing cells. This technique is based on the ability of a single-stranded DNA probe to anneal to complementary DNA (target DNA). This method also has some drawbacks. It detects only known genetic imbalances, it has limitations in resolution and lists of abnormalities this method can detect.
- Detection and identification of important chromosomal aberration(s) with prognostic effect in B-cell acute lymphoblastic leukemia
- Disease management and response to therapy
- As an adjunct to conventional chromosome studies in B-cell acute lymphoblastic leukemia
- Chromosomal abnormalities or a neoplastic clone is detected when the percent of cells with an abnormal clone exceeds the normal reference range for any given probe
- Positive result represents the detection of higher number of abnormal signals compare to normal reference for any given probe
- The absence of a neoplastic or abnormal clone does not rule out the presence of a neoplastic disorder
Negative for chromosomal abnormalities tested
Bone marrow, in sodium heparinized (Green top) vacutainer tube.
Stability
- Ambient - 24 hours
- Refrigerated - 3-5 days
- Frozen - unacceptable
- Hematol Oncol Clin North Am. 2009; 23(5):991-1010. [PMID: 19825449]
- Blood Rev. 2004 Jun;18(2):115-36. [PMID: 15010150]
- Clin J Oncol Nursing. 2016; 20(6):E147-54. [PMID: 27857258]
- Exp Hematol. 2015 Aug;43(8):640-53. [PMID: 26101161]
- Blood Rev. 2012 May;26(3):123-35. [PMID: 22436535]
- Williams Hematology, 9th ed, McGraw-Hill Education 2016: 173-91